Case number 1:22-cv-00856
Novo Nordisk Inc. et al v. Orbicular Pharmaceutical Technologies Pvt. Ltd., et al., > Documents
| Date Field | Doc. No. | Description (Pages) |
|---|---|---|
| Jun 30, 2023 | 161 | MOTION for Claim Construction re 69 Claim Construction Chart, 154 Claim Construction Chart - filed by Novo Nordisk A/S, Novo Nordisk Inc.. (Murray, Travis) (Entered: 06/30/2023) (3) |
| Jun 30, 2023 | 160 | Joint MOTION to Consolidate Cases (Case No. 22-897-CFC and Case No. 22-936-CFC Into Lead Case No. 22-856-CFC) - filed by Novo Nordisk A/S, Novo Nordisk Inc.. (Murray, Travis) (Entered: 06/30/2023) (8) |
| Jun 30, 2023 | 159 | Letter to The Honorable Colm F. Connolly from Travis J. Murray regarding joint motion for consolidation. (Murray, Travis) (Entered: 06/30/2023) (2) |
| Jun 30, 2023 | 158 | MOTION for Claim Construction re 69 Claim Construction Chart, 154 Claim Construction Chart - filed by Orbicular Pharmaceutical Technologies Pvt. Ltd.. (Farnan, Kelly) (Entered: 06/30/2023) (2) |
| Jun 29, 2023 | 157 | [SEALED] ANSWER to Amended Complaint, re: 137 Amended Complaint , COUNTERCLAIM against Novo Nordisk A/S, Novo Nordisk Inc. by Cipla USA, Inc., Cipla Ltd., Orbicular Pharmaceutical Technologies Pvt. Ltd..(Farnan, Kelly) (Entered: 06/29/2023) (0) |
| Jun 29, 2023 | 156 | [SEALED] ANSWER to Amended Complaint, re: 136 Amended Complaint , COUNTERCLAIM against Novo Nordisk A/S, Novo Nordisk Inc. by Cipla USA, Inc., Cipla Ltd., Orbicular Pharmaceutical Technologies Pvt. Ltd..(Farnan, Kelly) (Entered: 06/29/2023) (0) |
| Jun 28, 2023 | 154 | CLAIM Construction Chart by Novo Nordisk A/S, Novo Nordisk Inc.. (Attachments: # 1 Ex. A - '893 Patent)(Murray, Travis) (Entered: 06/28/2023) (Ex. A - '893 Patent) (9) |
| Jun 28, 2023 | 155 | NOTICE OF SERVICE of Plaintiffs' First Set of Requests for the Production of Documents and Things (Nos. 1-73) Directed to Defendants Orbicular Pharmaceutical Technologies Pvt. Ltd., Cipla Ltd., and Cipla USA, Inc. in C.A. No. 23-179-CFC filed by Novo Nordisk A/S, Novo Nordisk Inc..(Murray, Travis) (Entered: 06/28/2023) (4) |
| Jun 28, 2023 | 154 | CLAIM Construction Chart by Novo Nordisk A/S, Novo Nordisk Inc.. (Attachments: # 1 Ex. A - '893 Patent)(Murray, Travis) (Entered: 06/28/2023) (Main Document) (8) |
| Jun 26, 2023 | 153 | Amended ANSWER to 129 Answer to Amended Complaint, Counterclaim // Plaintiffs' Amended Answer to Sun Pharmaceutical Industries Ltd.'s Counterclaims - by Novo Nordisk A/S, Novo Nordisk Inc..(Murray, Travis) (Entered: 06/26/2023) (15) |
| Jun 26, 2023 | 152 | NOTICE OF SERVICE of Plaintiffs' Proposed Constructions of Claim Terms and Supporting Intrinsic Evidence for U.S. Patent No. 9,265,893 filed by Novo Nordisk A/S, Novo Nordisk Inc..(Murray, Travis) (Entered: 06/26/2023) (5) |
| Jun 23, 2023 | 150 | Amended Complaint* (1) |
| Jun 23, 2023 | 149 | REDACTED VERSION of 136 Amended Complaint by Novo Nordisk A/S, Novo Nordisk Inc.. (Attachments: # 1 Exs. A-E)(Murray, Travis) (Entered: 06/23/2023) (Exs. A-E) (30) |
| Jun 23, 2023 | 150 | REDACTED VERSION of 137 Amended Complaint by Novo Nordisk A/S, Novo Nordisk Inc.. (Attachments: # 1 Exs. A-K)(Murray, Travis) (Entered: 06/23/2023) (Exs. A-K) (30) |
| Jun 23, 2023 | 151 | NOTICE OF SERVICE of Proposed Constructions and Supporting Intrinsic Evidence filed by Orbicular Pharmaceutical Technologies Pvt. Ltd..(Haynes, Christine) (Entered: 06/23/2023) (2) |
| Jun 23, 2023 | 150 | REDACTED VERSION of 137 Amended Complaint by Novo Nordisk A/S, Novo Nordisk Inc.. (Attachments: # 1 Exs. A-K)(Murray, Travis) (Entered: 06/23/2023) (Main Document) (24) |
| Jun 23, 2023 | 149 | REDACTED VERSION of 136 Amended Complaint by Novo Nordisk A/S, Novo Nordisk Inc.. (Attachments: # 1 Exs. A-E)(Murray, Travis) (Entered: 06/23/2023) (Main Document) (14) |
| Jun 23, 2023 | 148 | REDACTED VERSION of 133 Stipulation, by Novo Nordisk A/S, Novo Nordisk Inc.. (Murray, Travis) (Entered: 06/23/2023) (30) |
| Jun 23, 2023 | 147 | REDACTED VERSION of 132 Stipulation, by Novo Nordisk A/S, Novo Nordisk Inc.. (Murray, Travis) (Entered: 06/23/2023) (30) |
| Jun 23, 2023 | 146 | REDACTED VERSION of 129 Answer to Amended Complaint, Counterclaim by Sun Pharmaceutical Industries Ltd., Sun Pharmaceutical Industries, Inc.. (Gaza, Anne) (Entered: 06/23/2023) (30) |
| Jun 21, 2023 | 145 | SO ORDERED, re 140 STIPULATION TO EXTEND TIME to file redacted version of D.I. 129 - Answer to the First Amended Complaint and Counterclaims to June 23, 2023 filed by Sun Pharmaceutical Industries, Inc., Sun Pharmaceutical Industries Ltd. Signed by Judge Colm F. Connolly on 6/20/2023. (nmf) (Entered: 06/21/2023) (2) |
| Jun 20, 2023 | 144 | Amended ANSWER to 123 Answer to Amended Complaint, Counterclaim --Plaintiffs' Amended Answer to Biocon's Counterclaims-- by Novo Nordisk A/S, Novo Nordisk Inc..(Murray, Travis) (Entered: 06/20/2023) (15) |
| Jun 20, 2023 | 143 | Amended ANSWER to 122 Answer to Amended Complaint, Counterclaim --Plaintiffs' Amended Answer to Orbicular Pharmaceutical Technologies Pvt. Ltd.'s Counterclaims-- by Novo Nordisk A/S, Novo Nordisk Inc..(Murray, Travis) (Entered: 06/20/2023) (13) |
| Jun 20, 2023 | 142 | NOTICE OF SERVICE of Preliminary Identification Claim Terms filed by Orbicular Pharmaceutical Technologies Pvt. Ltd..(Haynes, Christine) (Entered: 06/20/2023) (2) |
| Jun 20, 2023 | 141 | NOTICE OF SERVICE of Plaintiffs' Preliminary Identification of Claim Terms and Proposed Constructions of U.S. Patent No. 9,265,893 filed by Novo Nordisk A/S, Novo Nordisk Inc..(Murray, Travis) (Entered: 06/20/2023) (5) |
| Jun 20, 2023 | 140 | STIPULATION TO EXTEND TIME to file redacted version of D.I. 129 - Answer to the First Amended Complaint and Counterclaims to June 23, 2023 - filed by Sun Pharmaceutical Industries Ltd., Sun Pharmaceutical Industries, Inc.. (Vrana, Robert) (Entered: 06/20/2023) (2) |
| Jun 16, 2023 | 139 | NOTICE OF SERVICE of Novo Nordisk's Initial Responses to Orbicular's Invalidity Contentions in C.A. No. 23-179-CFC Regarding U.S. Patent Nos. 8,114,833 and 9,265,893 and Amended Responses to Defendants' Invalidity Contentions in C.A. Nos. 22-856-CFC, 22-896-CFC, and 22-937-CFC Regarding U.S. Patent Nos. 8,114,833; 8,920,383; 9,775,953; and 9,265,893 - filed by Novo Nordisk A/S, Novo Nordisk Inc..(Murray, Travis) (Entered: 06/16/2023) (7) |
| Jun 16, 2023 | 138 | NOTICE OF SERVICE of Plaintiffs' Initial Infringement Contentions as to Orbicular Pharmaceutical Technologies Pvt. Ltd. in C.A. No. 23-179 (CFC) - filed by Novo Nordisk A/S, Novo Nordisk Inc..(Murray, Travis) (Entered: 06/16/2023) (5) |
| Jun 16, 2023 | 137 | [SEALED] SECOND AMENDED COMPLAINT against Cipla Ltd., Cipla USA, Inc., Orbicular Pharmaceutical Technologies Pvt. Ltd.- filed by Novo Nordisk Inc., Novo Nordisk A/S. (Attachments: # 1 Exhibits A-K)(kmd) (Entered: 06/16/2023) (0) |
| Jun 16, 2023 | 136 | [SEALED] FIRST AMENDED COMPLAINT against Orbicular Pharmaceutical Technologies Pvt. Ltd., Cipla Ltd., Cipla USA, Inc.- filed by Novo Nordisk Inc., Novo Nordisk A/S. (Attachments: # 1 Exhibits A-E)(kmd) (Entered: 06/16/2023) (0) |
| Jun 15, 2023 | 135 | [SEALED] SO ORDERED, re 133 Stipulation to Amend Complaint Against Orbicular Pharmaceutical Technologies Pvt. Ltd. in C.A. No. 22-856-CFC, filed by Novo Nordisk A/S, Novo Nordisk Inc. Signed by Judge Colm F. Connolly on 6/15/2023.This order has been emailed to local counsel. (kmd) (Entered: 06/15/2023) (0) |
| Jun 15, 2023 | 134 | [SEALED] SO ORDERED, re 132 Stipulation to Amend Complaint Against Orbicular Pharmaceutical Technologies Pvt. Ltd. in C.A. No. 23-179-CFC, filed by Novo Nordisk A/S, Novo Nordisk Inc. Signed by Judge Colm F. Connolly on 6/15/2023.This order has been emailed to local counsel. (kmd) (Entered: 06/15/2023) (0) |
| Jun 15, 2023 | 133 | [SEALED] STIPULATION and [Proposed] Order to Amend Complaint Against Orbicular Pharmaceutical Technologies Pvt. Ltd. in C.A. No. 22-856-CFC - by Novo Nordisk A/S, Novo Nordisk Inc.. (Attachments: # 1 Ex. 1 - 2nd Amd. Complaint, # 2 Exs. A-K to 2nd Amd. Complaint., # 3 Ex. 2 - Redline)(Murray, Travis) (Entered: 06/15/2023) (0) |
| Jun 15, 2023 | 132 | [SEALED] STIPULATION and [Proposed] Order to Amend Complaint Against Orbicular Pharmaceutical Technologies Pvt. Ltd. in C.A. No. 23-179-CFC - by Novo Nordisk A/S, Novo Nordisk Inc.. (Attachments: # 1 Ex. 1 - First Amended Complaint, # 2 Exs. A-E to Amd. Complaint, # 3 Ex. 2 - Redline)(Murray, Travis) (Entered: 06/15/2023) (0) |
| Jun 15, 2023 | 131 | REDACTED VERSION of 127 Appendix - by Novo Nordisk A/S, Novo Nordisk Inc.. (Murray, Travis) (Entered: 06/15/2023) (30) |
| Jun 15, 2023 | 130 | REDACTED VERSION of 126 Joint Claim Construction Brief - by Novo Nordisk A/S, Novo Nordisk Inc.. (Murray, Travis) (Entered: 06/15/2023) (30) |
| Jun 12, 2023 | 129 | [SEALED] ANSWER to Amended Complaint, re: 104 Amended Complaint , COUNTERCLAIM against All Plaintiffs by Sun Pharmaceutical Industries, Inc., Sun Pharmaceutical Industries Ltd..(Gaza, Anne) (Entered: 06/12/2023) (0) |
| Jun 12, 2023 | 128 | REDACTED VERSION of 123 Answer to Amended Complaint, Counterclaim by Biocon Ltd., Biocon Pharma Ltd., Biocon Pharma, Inc.. (Dorsney, Kenneth) (Entered: 06/12/2023) (30) |
| Jun 9, 2023 | 127 | [SEALED] APPENDIX re 126 Joint Claim Construction Brief - by Novo Nordisk A/S, Novo Nordisk Inc.. (Murray, Travis) (Entered: 06/09/2023) (0) |
| Jun 9, 2023 | 126 | [SEALED] JOINT CLAIM CONSTRUCTION BRIEF - filed by Novo Nordisk Inc., Novo Nordisk A/S. (Murray, Travis) (Entered: 06/09/2023) (0) |
| Jun 8, 2023 | 125 | NOTICE OF SERVICE of Fourth Set of Requests for Production of Documents and Things (No. 76) filed by Orbicular Pharmaceutical Technologies Pvt. Ltd..(Haynes, Christine) (Entered: 06/08/2023) (2) |
| Jun 7, 2023 | 124 | REDACTED VERSION of 122 Answer to Amended Complaint, Counterclaim by Orbicular Pharmaceutical Technologies Pvt. Ltd.. (Farnan, Kelly) (Entered: 06/07/2023) (30) |
| Jun 5, 2023 | 123 | [SEALED] ANSWER to Amended Complaint, re: 105 Amended Complaint , COUNTERCLAIM against Novo Nordisk A/S, Novo Nordisk Inc. by Biocon Pharma Ltd., Biocon Ltd., Biocon Pharma, Inc..(Dorsney, Kenneth) (Entered: 06/05/2023) (0) |
| Jun 5, 2023 | 122 | [SEALED] ANSWER to Amended Complaint, re: 106 Amended Complaint , COUNTERCLAIM against Novo Nordisk A/S, Novo Nordisk Inc. by Orbicular Pharmaceutical Technologies Pvt. Ltd..(Farnan, Kelly) (Entered: 06/05/2023) (0) |
| Jun 5, 2023 | 121 | STIPULATION TO EXTEND TIME for Sun Defendants to answer, move, or otherise respond to the First Amended Complaint to June 12, 2023 - filed by Sun Pharmaceutical Industries Ltd., Sun Pharmaceutical Industries, Inc.. (Vrana, Robert) (Entered: 06/05/2023) (2) |
| Jun 2, 2023 | 120 | NOTICE OF SERVICE of Orbiculars Sur-Reply Claim Construction Brief filed by Orbicular Pharmaceutical Technologies Pvt. Ltd..(Haynes, Christine) (Entered: 06/02/2023) (2) |
| Jun 1, 2023 | 118 | NOTICE OF SERVICE of 1) Defendant Sun Pharmaceutical Industries Ltd. and Sun Pharmaceutical Industries, Inc. Amended Initial Invalidty Contentions; and 2) Sun Pharmaceutical Industries Ltd. and Sun Pharmaceutical Industries, Inc. Amended Noninfringement Contentions filed by Sun Pharmaceutical Industries Ltd., Sun Pharmaceutical Industries, Inc..(Vrana, Robert) (Entered: 06/01/2023) (2) |
| Jun 1, 2023 | 119 | NOTICE OF SERVICE of (1) Biocon Defendants' Initial Invalidity Contentions regarding the '893 Patent and; (2) Biocon Defendants' Preliminary Non-Infringement Contentions regarding the '893 Patent filed by Biocon Ltd., Biocon Pharma Ltd., Biocon Pharma, Inc..(Dorsney, Kenneth) (Entered: 06/01/2023) (2) |
| Jun 1, 2023 | 117 | NOTICE OF SERVICE of (1) Orbicular Pharmaceutical Technology Pvt. Ltd.s Invalidity Contentions (22-856- CFC and 23-179-CFC); (2) Orbicular Pharmaceutical Technology Pvt. Ltd.s Non-Infringement Contentions (23-179-CFC); and (3) Orbicular Pharmaceutical Technology Pvt. Ltd.s Supplemental Non-Infringement Contentions (22-856-CFC) filed by Orbicular Pharmaceutical Technologies Pvt. Ltd..(Haynes, Christine) (Entered: 06/01/2023) (2) |
| May 31, 2023 | 115 | Complaint* (1) |
| May 31, 2023 | 116 | Amended Complaint* (1) |
| May 30, 2023 | 112 | Amended Complaint* (1) |
| May 30, 2023 | 114 | Amended Complaint* (1) |
| May 30, 2023 | 111 | Complaint* (1) |
| May 30, 2023 | 113 | Complaint* (1) |
| Nov 30, 2022 | 34 | NOTICE OF SERVICE of Defendant Biocon's Initial 26(a) and Paragraph 3 Disclosures filed by Biocon Ltd., Biocon Pharma Ltd., Biocon Pharma, Inc..(Dorsney, Kenneth) (Entered: 11/30/2022) (2) |
| Nov 29, 2022 | 33 | SO ORDERED, re 31 Stipulation to Extend the Deadline to Submit ESI Order and Protective Order, filed by Novo Nordisk A/S, Novo Nordisk Inc. Signed by Judge Colm F. Connolly on 11/29/2022. (kmd) (Entered: 11/29/2022) (2) |
| Nov 29, 2022 | 32 | NOTICE OF SERVICE of (1) Plaintiffs' Disclosures to Biocon Pharma Ltd., Biocon Ltd., and Biocon Pharma, Inc. Under Paragraph 3 of the District of Delaware Default Standard and (2) Plaintiffs' Disclosures to Biocon Pharma Ltd., Biocon Ltd., and Biocon Pharma, Inc. Pursuant to Rule 26(A)(1) of the Federal Rules of Civil Procedure - filed by Novo Nordisk A/S, Novo Nordisk Inc..(Murray, Travis) (Entered: 11/29/2022) (5) |
| Nov 29, 2022 | 31 | STIPULATION and [Proposed] Order to Extend the Deadline to Submit ESI Order and Protective Order - by Novo Nordisk A/S, Novo Nordisk Inc.. (Murray, Travis) (Entered: 11/29/2022) (2) |
| Nov 28, 2022 | 30 | SO ORDERED, re 26 STIPULATION TO EXTEND TIME for Plaintiffs and Biocon to make their disclosures required by FED. R. CIV. P. 26(a)(1) and their initial disclosures required by Paragraph 3 of the District of Delaware Default Standard to November 29, 2022, filed by Novo Nordisk A/S, Novo Nordisk Inc. Signed by Judge Colm F. Connolly on 11/28/2022. (kmd) (Entered: 11/28/2022) (2) |
| Nov 23, 2022 | 29 | NOTICE OF SERVICE of Plaintiffs Novo Nordisk Inc. and Novo Nordisk A/S's Production Pursuant to Paragraph 5 of the Scheduling Order (D.I. 21), Including Bates Range NN_SAX-CONSOL_00000001 - NN_SAX-CONSOL_00008964 filed by Novo Nordisk A/S, Novo Nordisk Inc..(Murray, Travis) (Entered: 11/23/2022) (7) |
| Nov 22, 2022 | 28 | NOTICE OF SERVICE of 1) Initial Disclosures of Sun Pharmaceutical Industries Ltd. and Sun Pharmaceutical Industries, Inc., and 2) Initial Disclosures of Sun Pharmaceutical Industries Ltd. and Sun Pharmaceutical Industries, Inc., Pursuant to Paragraph 3 of the Default Standard for Discovery filed by Sun Pharmaceutical Industries Ltd., Sun Pharmaceutical Industries, Inc..(Vrana, Robert) (Entered: 11/22/2022) (2) |
| Nov 22, 2022 | 27 | NOTICE OF SERVICE of (1) Orbicular Pharmaceutical Technology Pvt. Ltd.s Initial Disclosures Pursuant to Fed. R. Civ. P. 26(a)(1); and (2) Orbicular Pharmaceutical Technology Pvt. Ltd.s Disclosures Pursuant to Paragraph 3 of the Delaware Default Standard for Discovery filed by Orbicular Pharmaceutical Technologies Pvt. Ltd..(Haynes, Christine) (Entered: 11/22/2022) (2) |
| Nov 22, 2022 | 26 | STIPULATION TO EXTEND TIME for Plaintiffs and Biocon to make their disclosures required by FED. R. CIV. P. 26(a)(1) and their initial disclosures required by Paragraph 3 of the District of Delaware Default Standard to November 29, 2022 - filed by Novo Nordisk A/S, Novo Nordisk Inc.. (Murray, Travis) (Entered: 11/22/2022) (2) |
| Nov 22, 2022 | 25 | NOTICE OF SERVICE of Plaintiffs' Preliminary Disclosure of Asserted Patents and Claims to Defendant Biocon filed by Novo Nordisk A/S, Novo Nordisk Inc..(Murray, Travis) (Entered: 11/22/2022) (5) |
| Nov 22, 2022 | 24 | NOTICE OF SERVICE of (1) Plaintiffs' Preliminary Disclosure of Asserted Patents and Claims as to Defendant Orbicular; (2) Plaintiffs' Disclosures to Orbicular Pharmaceutical Technologies Pvt. Ltd. Under Paragraph 3 of the District of Delaware Default Standard; and (3) Plaintiffs' Disclosures to Orbicular Pharmaceutical Technologies Pvt. Ltd. Pursuant to Rule 26(a)(1) of the Federal Rules of Civil Procedure filed by Novo Nordisk A/S, Novo Nordisk Inc..(Murray, Travis) (Entered: 11/22/2022) (5) |
| Nov 22, 2022 | 23 | NOTICE OF SERVICE of (1) Plaintiffs' Preliminary Disclosure of Asserted Patents and Claims as to Defendant Sun; (2) Plaintiffs' Disclosures to Sun Pharmaceutical Industries Ltd. and Sun Pharmaceutical Industries Inc. Under Paragraph 3 of the District of Delaware Default Standard; and (3) Plaintiffs' Disclosures to Sun Pharmaceutical Industries Ltd. and Sun Pharmaceutical Industries Inc. Pursuant to Rule 26(a)(1) of the Federal Rules of Civil Procedure filed by Novo Nordisk A/S, Novo Nordisk Inc..(Murray, Travis) (Entered: 11/22/2022) (4) |
| Nov 11, 2022 | 22 | NOTICE of Change of Firm Affiliation of Co-Counsel by Sun Pharmaceutical Industries Ltd., Sun Pharmaceutical Industries, Inc. (Vrana, Robert) (Entered: 11/11/2022) (4) |
| Nov 8, 2022 | 21 | SCHEDULING & CONSOLIDATION ORDER: THESE ACTIONS ARE CONSOLIDATED FOR ALL PURPOSES AND ALL FUTURE FILINGS SHALL BE MADE IN LEAD CASE NO. 22-CV-856-CFC ONLY. The caption shall be modified to include the words "ANDA CASE" immediately below the civil action number. Joinder of Parties due by 8/25/2023. Amended Pleadings due by 8/25/2023. Fact Discovery completed by 10/6/2023. Expert Discovery due by 2/16/2024. Joint Claim Construction Brief due by 6/9/2023. A Markman Hearing is set for 7/11/2023 at 09:00 AM in Courtroom 4B before Judge Colm F. Connolly. Proposed Pretrial Order due by 4/16/2024. A Final Pretrial Conference is set for 5/7/2024 at 03:00 PM in Courtroom 4B before Judge Colm F. Connolly. A Bench Trial is set for 5/13/2024 at 08:30 AM in Courtroom 4B before Judge Colm F. Connolly. Signed by Judge Colm F. Connolly on 11/8/2022. (nmf) (Entered: 11/08/2022) (30) |
| Oct 27, 2022 | 20 | PROPOSED ORDER -- [Proposed] Scheduling Order -- by Novo Nordisk A/S, Novo Nordisk Inc.. (Attachments: # 1 Letter to The Honorable Colm F. Connolly)(Murray, Travis) (Entered: 10/27/2022) (Letter to The Honorable Colm F. Connolly) (1) |
| Oct 27, 2022 | 20 | PROPOSED ORDER -- [Proposed] Scheduling Order -- by Novo Nordisk A/S, Novo Nordisk Inc.. (Attachments: # 1 Letter to The Honorable Colm F. Connolly)(Murray, Travis) (Entered: 10/27/2022) (Main Document) (30) |
| Oct 20, 2022 | 19 | STIPULATION TO EXTEND TIME for the parties to file a proposed scheduling order to October 27, 2022 - filed by Novo Nordisk A/S, Novo Nordisk Inc.. (Murray, Travis) (Entered: 10/20/2022) (2) |
| Oct 17, 2022 | 18 | MOTION for Pro Hac Vice Appearance of Attorney Aryeh N. Feinstein - filed by Orbicular Pharmaceutical Technologies Pvt. Ltd.. (Farnan, Kelly) (Entered: 10/17/2022) (3) |
| Oct 11, 2022 | 17 | SO ORDERED, re 15 STIPULATION TO EXTEND TIME to submit a proposed scheduling order to October 20, 2022, filed by Novo Nordisk A/S, Novo Nordisk Inc. Ordered by Judge Colm F. Connolly on 10/11/2022. (kmd) (Entered: 10/11/2022) (2) |
| Oct 7, 2022 | 16 | Letter to The Honorable Colm F. Connolly from Brian P. Egan regarding the Court's Order on coordination of related cases - re (14 in 1:22-cv-00896-CFC, 14 in 1:22-cv-00896-CFC) Order,,, Set Deadlines,, (16 in 1:22-cv-00937-CFC, 16 in 1:22-cv-00937-CFC) Order,,, Set Deadlines,, (13 in 1:22-cv-00856-CFC, 13 in 1:22-cv-00856-CFC) Order,,, Set Deadlines,,. (Egan, Brian) (Entered: 10/07/2022) (2) |
| Oct 7, 2022 | 15 | STIPULATION TO EXTEND TIME to submit a proposed scheduling order to October 20, 2022 - filed by Novo Nordisk A/S, Novo Nordisk Inc.. (Murray, Travis) (Entered: 10/07/2022) (2) |
| Sep 19, 2022 | 14 | ANSWER to 9 Answer to Complaint, Counterclaim -- Answer to Counterclaims -- by Novo Nordisk A/S, Novo Nordisk Inc..(Murray, Travis) (Entered: 09/19/2022) (29) |
| Sep 7, 2022 | 13 | ORDER, This case having been recently joined and as this case is listed as related to earlier filed cases that are currently proceeding on an agreed upon schedule entered by the Court; IT IS ORDERED that, on or before October 7, 2022, counsel for the parties shall confer regarding coordination of the cases and submit a proposed scheduling order to the Court or otherwise advise the Court that a separate scheduling conference is needed. ORDER, Setting Deadlines: ( Notice of Compliance deadline set for 10/7/2022.) Signed by Judge Colm F. Connolly on 9/7/2022. (nmf) (Entered: 09/07/2022) (1) |
| Sep 6, 2022 | 12 | NOTICE of Appearance by Christine Dealy Haynes on behalf of Orbicular Pharmaceutical Technologies Pvt. Ltd. (Haynes, Christine) (Entered: 09/06/2022) (2) |
| Aug 29, 2022 | 11 | MOTION for Pro Hac Vice Appearance of Attorney William R. Zimmerman, Joseph M. Reisman, William O. Adams, Karen M. Cassidy Selvaggio and Nicholas A. Belair - filed by Orbicular Pharmaceutical Technologies Pvt. Ltd.. (Farnan, Kelly) (Entered: 08/29/2022) (7) |
| Aug 29, 2022 | 10 | Disclosure Statement pursuant to Rule 7.1: No Parents or Affiliates Listed filed by Orbicular Pharmaceutical Technologies Pvt. Ltd.. (Farnan, Kelly) (Entered: 08/29/2022) (2) |
| Aug 29, 2022 | 9 | ANSWER to 1 Complaint , COUNTERCLAIM against Novo Nordisk A/S, Novo Nordisk Inc. by Orbicular Pharmaceutical Technologies Pvt. Ltd..(Farnan, Kelly) (Entered: 08/29/2022) (30) |
| Aug 22, 2022 | 8 | MOTION for Pro Hac Vice Appearance of Attorney Jeffrey J. Oelke, Ryan P. Johnson, Robert E. Counihan, Laura T. Moran, Erica R. Sutter and Olivia L. Wheeling - filed by Novo Nordisk A/S, Novo Nordisk Inc.. (Egan, Brian) (Entered: 08/22/2022) (12) |
| Jul 5, 2022 | 7 | Waiver of Service Executed (1) Docket Text: WAIVER OF SERVICE returned executed by Novo Nordisk Inc., Novo Nordisk A/S: For Orbicular Pharmaceutical Technologies Pvt. Ltd. waiver sent on 6/28/2022, answer due 8/29/2022. (Egan, Brian) |
| Jun 29, 2022 | N/A | Case Assigned/Reassigned (0) Docket Text: Case Assigned to Judge Colm F. Connolly. Please include the initials of the Judge (CFC) after the case number on all documents filed. (rjb) |
| Jun 24, 2022 | 1 | Complaint* (1) |
| Jun 24, 2022 | 6 | Summons Issued (2) Docket Text: Summons Issued as to Orbicular Pharmaceutical Technologies Pvt. Ltd. on 6/24/2022. (twk) |
| Jun 24, 2022 | 5 | Disclosure Statement (2) Docket Text: Disclosure Statement pursuant to Rule 7.1: identifying Corporate Parent Novo A/S for Novo Nordisk A/S; Corporate Parent Novo Nordisk US Holdings, Inc. for Novo Nordisk Inc. filed by Novo Nordisk A/S, Novo Nordisk Inc. (twk) |
| Jun 24, 2022 | 4 | Patent/Trademark Report to Commissioner (2) Docket Text: Report to the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 7,762,994 B2; 8,114,833 B2; 8,579,869 B2; 8,684,969 B2; 8,920,383 B2; 9,108,002 B2; 9,132,239 B2; 9,457,154 B2; 9,616,180 B2; 9,687,611 B2; 9,775,953 B2; 9,861,757 B2; 10,220,155 B2; 10,357,616 B2; 10,376,652 B2; 11,097,063 B2; 11,311,679 B2; RE46,363 E. (twk) |
| Jun 24, 2022 | 3 | ANDA Form (1) Docket Text: Supplemental information for patent cases involving an Abbreviated New Drug Application (ANDA) - Date Patentee(s) Received Notice: May 14, 2022. Date of Expiration of Patent: See attached. Thirty Month Stay Deadline: 11/14/2024. (twk) |
| Jun 24, 2022 | 2 | Magistrate Consent Forms (3) Docket Text: Notice, Consent and Referral forms re: U.S. Magistrate Judge jurisdiction. (twk) |
| Jun 24, 2022 | 1 | Civil Cover Sheet (2) |
| Jun 24, 2022 | 1 | Exhibit A-R (303) |
| Jun 24, 2022 | 1 | Main Document (25) Docket Text: COMPLAINT filed against Orbicular Pharmaceutical Technologies Pvt. Ltd. ( Filing fee $ 402, receipt number ADEDC-3903411.) - filed by Novo Nordisk Inc., Novo Nordisk A/S. (Attachments: # (1) Exhibit A-R, # (2) Civil Cover Sheet)(twk) |
